Latest On Cancer Genetics, Inc (CGIX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-03-25 11:15 EST | News | Cancer Genetics stock up on shareholder approval for Stemonix deal | N/A |  |
| 2021-03-12 22:13 EST | News | Cancer Genetics (CGIX) Investor Presentation - Slideshow | N/A | |
| 2021-02-11 04:37 EST | News | Cancer Genetics more than doubles after merger terms update | N/A | |
| 2021-02-11 04:36 EST | News | Cancer Genetics to raise $17.5M via stock offering | N/A | |
| 2021-01-29 15:38 EST | News | Cancer Genetics under pressure after $10M capital raise | N/A | |
| 2020-12-13 03:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 19:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-12 19:57 EST | News | Cancer Genetics reports Q3 results | N/A | |
| 2020-11-07 15:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 17:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-30 13:57 EST | News | Cancer Genetics plummets 38% after raising 'bought deal' offering to $3M | N/A | |
| 2020-09-19 08:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-25 04:25 EST | News | Cancer Genetics skyrockets on acquisition of StemoniX | N/A | |
| 2020-08-14 16:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 15:33 EST | News | Cancer Genetics reports Q2 results | N/A | |
| 2020-07-31 00:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 16:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-10 08:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 08:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-27 15:11 EST | News | Mixed shelf roundup - healthcare | N/A | |
| 2020-06-27 00:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:57 EST | News | Cancer Genetics reports Q1 results | N/A | |
| 2020-06-03 12:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-01 21:17 EST | News | Cancer Genetics reports Q4 results | N/A | |
| 2020-05-31 16:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-03 08:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-07 00:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 23:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 03:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 03:25 EST | Earnings | Earnings have been released on March 23, 2017, with -$4.42 earnings per share. | Sell | |
| 2020-02-21 23:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-06 23:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-29 23:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-28 03:25 EST | Earnings | Earnings have been released on August 15, 2017, with -$4.85 earnings per share. | Sell | |
| 2020-01-28 03:25 EST | Earnings | Earnings have been released on December 31, 2018, with -$4.20 earnings per share. | Sell | |
| 2020-01-28 03:25 EST | Earnings | Earnings have been released on November 20, 2018, with -$9.34 earnings per share. | Sell | |
| 2020-01-28 03:25 EST | Earnings | Earnings have been released on May 15, 2018, with -$4.94 earnings per share. | Sell | |
| 2020-01-27 23:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-15 23:20 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-21 23:12 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-16 23:20 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-06 13:59 EST | News | TRNX, YEXT, BIG and CGIX among midday movers | N/A | |
| 2019-12-06 12:17 EST | News | Clovis Oncology among healthcare gainers; Curis among losers | N/A | |
| 2019-11-29 11:37 EST | News | X, NVAX, PIR and SVRA among midday movers | N/A | |
| 2019-11-27 23:20 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-26 23:20 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-22 23:18 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-22 13:08 EST | News | BKE, GSX, HEXO and PSTG among midday movers | N/A | |
| 2019-11-22 11:08 EST | News | EyeGate Pharmaceuticals leads healthcare gainers; HEXO and Recro Pharma among losers | N/A | |
About Cancer Genetics, Inc (CGIX):
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.
General
- Name Cancer Genetics, Inc
- Symbol CGIX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 110
- Last Split Factor1:30
- Last Split Date2019-10-25
- Fiscal Year EndDecember
- IPO Date2013-04-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.cancergenetics.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 2.25
- Price/Book (Most Recent Quarter) 14.31
- Enterprise Value Revenue 10.71
View More
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin -72%
- Operating Margin -58%
- Return on Assets -15%
- Return on Equity -69%
- Revenue 6.33 million
- Earnings Per Share -$0.52
- Revenue Per Share $2.9
- Gross Profit 3.6 million
- Quarterly Earnings Growth -24.2%
View More
Highlights
- Market Capitalization 66.12 million
- EBITDA -15285000
- PEG Ratio -0.08
- Analyst Target Price $3
- Book Value Per Share $1.92
View More
Share Statistics
- Shares Outstanding 10.56 million
- Shares Float 3.51 million
- % Held by Insiders 749%
- % Held by Institutions 16.92%
- Shares Short 494219
- Shares Short Prior Month 1.15 million
- Short Ratio 0.11
- Short % of Float 5%
- Short % of Shares Outstanding 5%
View More
Technicals
- Beta 2.72
- 52 Week High $7.7
- 52 Week Low $1.98
- 50 Day Moving Average 5.7
- 200 Day Moving Average 3.97
View More
Dividends
- Dividend Date 2019-10-25
- ExDividend Date N/A
- Dividend Yield 0%
View More
Cancer Genetics, Inc (CGIX) Dividend Calendar:
CGIX's last dividend payment was made to shareholders on October 25, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Cancer Genetics, Inc (CGIX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-12 | $N/A | -$0.58 | ||
| 2020-06-30 | 2020-09-30 | $N/A | -$0.58 | ||
| 2020-03-31 | 2020-06-30 | $N/A | -$0.82 | ||
| 2019-12-31 | 2020-03-31 | $1.89 million | -$0.56 | ||
| 2019-09-30 | 2019-12-31 | $2.07 million | $0.12 | ||
| 2019-06-30 | 2019-09-30 | $1.53 million | -$2.38 | ||
| 2019-03-31 | 2019-06-30 | $1.82 million | -$0.24 | -$4.80 | 95.03% |
| 2018-12-31 | 2019-03-31 | $6.83 million | -$1.06 | -$4.80 | 77.83% |
| 2018-09-30 | 2018-11-19 | $5.94 million | -$9.30 | -$5.10 | -82.35% |
| 2018-06-30 | 2018-08-14 | $7.04 million | -$3.90 | -$4.65 | 16.13% |
| 2018-03-31 | 2018-05-15 | $7.67 million | -$4.80 | -$3.90 | -23.08% |
| 2017-09-30 | 2017-11-09 | $8.03 million | -$0.90 | -$3.80 | 76.32% |
| 2017-06-30 | 2017-08-14 | $6.6 million | -$4.20 | -$4.50 | 6.67% |
| 2017-03-31 | 2017-05-11 | $6.97 million | -$15.30 | -$5.40 | -183.33% |
| 2016-12-31 | 2017-03-23 | $7.23 million | -$4.50 | -$6.45 | 30.23% |
| 2016-09-30 | 2016-11-09 | $6.75 million | -$6.90 | -$8.25 | 16.36% |
| 2016-06-30 | 2016-08-09 | $7 million | -$8.40 | -$9.90 | 15.15% |
| 2016-03-31 | 2016-05-10 | $6.07 million | -$11.70 | -$12.75 | 8.24% |
| 2015-12-31 | 2016-03-10 | $5.48 million | -$14.10 | -$13.80 | -2.17% |
| 2015-09-30 | 2015-11-09 | $4 million | -$0.56 | -$0.49 | -14.29% |
| 2015-06-30 | 2015-08-11 | $4.19 million | -$0.51 | -$0.51 | 0% |
| 2015-03-31 | 2015-05-11 | $4.37 million | -$0.44 | -$0.54 | 18.52% |
| 2014-12-31 | 2015-03-12 | $4.04 million | -$0.54 | -$0.50 | -8% |
| 2014-09-30 | 2014-11-10 | $3.22 million | -$0.51 | -$0.48 | -6.25% |
| 2014-06-30 | 2014-08-14 | $1.51 million | -$13.50 | -$11.10 | -21.62% |
| 2014-03-31 | 2014-05-15 | $1.43 million | -$8.10 | -$8.80 | 7.95% |
| 2013-12-31 | 2014-03-26 | $1.86 million | -$9.30 | -$10.80 | 13.89% |
| 2013-09-30 | 2013-11-13 | $1.71 million | -$18.30 | -$21.15 | 13.48% |
| 2013-06-30 | 2013-08-05 | $1.83 million | -$17.40 | -$15.90 | -9.43% |
| 2013-03-31 | 2013-05-29 | $1.22 million | -$9.99 |
Cancer Genetics, Inc (CGIX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | N/A |
| Income Before Tax | N/A | N/A | N/A | 252000 | -4.8 million |
| Selling General Administrative | N/A | N/A | N/A | 1.03 million | 1.61 million |
| Gross Profit | N/A | N/A | N/A | 819000 | 1.11 million |
| Ebit | N/A | N/A | N/A | 749000 | -503000 |
| Operating Income | N/A | N/A | N/A | -210000 | -503000 |
| Income Tax Expense | 2000 | N/A | 6000 | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | 1.89 million | 2.07 million |
| Cost of Revenue | N/A | N/A | N/A | 1.07 million | 960000 |
| Total Other Income Expense Net | N/A | N/A | N/A | 464000 | -4.3 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | 252000 | -4.8 million |
| Net Income Applicable to Common Shares | -1.35 million | -1.7 million | -1.18 million | -293000 | 1.98 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | 6.64 million | N/A |
| Change to Liabilities | 79000 | 191000 | 130000 | -3.06 million | 1.42 million |
| Total Cash Flow from Investing Activities | 38000 | 897000 | 28000 | 6.64 million | 2.51 million |
| Net Borrowings | -93000 | -160000 | -163000 | -1.97 million | -2000 |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -1.98 million | -263000 |
| Change to Operating Activities | -602000 | -651000 | 1.29 million | 175000 | -562000 |
| Change in Cash | N/A | N/A | N/A | 1.73 million | 1.48 million |
| Total Cash from Operating Activities | -1.67 million | -1.74 million | -164000 | -3.12 million | -679000 |
| Depreciation | N/A | N/A | N/A | 387000 | 118000 |
| Other Cash Flow from Investing Activities | 38000 | 900000 | 28000 | 9.68 million | -528000 |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | 117000 | -121000 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | 84000 | -261000 |
| Change to Net Income | 115000 | -108000 | -394000 | -471000 | -3.5 million |
| Capital Expenditures | N/A | N/A | N/A | N/A | 50000 |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | 7.52 million | 13.37 million |
| Total Stockholder Equity | N/A | N/A | N/A | 7.39 million | 7.46 million |
| Other Current Liabilities | 1.8 million | N/A | N/A | 2.15 million | 5.31 million |
| Total Assets | N/A | N/A | N/A | 14.9 million | 20.84 million |
| Common Stock | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | 895000 | N/A | N/A | 1.29 million | 2.85 million |
| Retained Earnings | -168.66 million | -167.3 million | -165.6 million | -164.42 million | -164.13 million |
| Other Liabilities | 45000 | 98000 | 170000 | 430000 | 520000 |
| Other Assets | 645000 | 692000 | 836000 | 997000 | 1.24 million |
| Cash | N/A | N/A | N/A | 3.88 million | 2.15 million |
| Total Current Liabilities | 4.75 million | N/A | N/A | 6.97 million | 12.68 million |
| Other Stockholder Equity | -56000 | -27000 | 130000 | 26000 | -101000 |
| Property, Plant & Equipment | 535000 | 647000 | 582000 | 652000 | 786000 |
| Total Current Assets | 2.8 million | N/A | N/A | 7.18 million | 12.6 million |
| Long Term Investments | N/A | N/A | N/A | 92000 | 92000 |
| Net Tangible Assets | -848000 | -670000 | 474000 | 1.4 million | 1.35 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 2.86 million | N/A | N/A | N/A | 3.33 million |
Cancer Genetics, Inc (CGIX) Chart:
Cancer Genetics, Inc (CGIX) News:
Below you will find a list of latest news for Cancer Genetics, Inc (CGIX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Cancer Genetics, Inc (CGIX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Cancer Genetics, Inc (CGIX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1349929/000149315220011939/0001493152-20-011939-index.htm |
| 2020-07-06 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1349929/000000000020006001/0000000000-20-006001-index.htm |
| 2019-02-15 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1349929/000088430019000005/0000884300-19-000005-index.htm |
| 2019-01-14 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000049/0000905718-19-000049-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000053/0000905718-19-000053-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000055/0000905718-19-000055-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000057/0000905718-19-000057-index.htm |
| 2019-02-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000094/0000905718-19-000094-index.htm |
| 2019-02-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000095/0000905718-19-000095-index.htm |
| 2019-02-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000096/0000905718-19-000096-index.htm |
| 2019-02-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000097/0000905718-19-000097-index.htm |
| 2019-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000555/0000905718-19-000555-index.htm |
| 2019-08-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000698/0000905718-19-000698-index.htm |
| 2019-08-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000700/0000905718-19-000700-index.htm |
| 2019-08-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000702/0000905718-19-000702-index.htm |
| 2019-08-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000704/0000905718-19-000704-index.htm |
| 2019-08-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000723/0000905718-19-000723-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1349929/000093583619000102/0000935836-19-000102-index.htm |
| 2020-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1349929/000103738920000010/0001037389-20-000010-index.htm |
| 2018-07-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1349929/000114036118033906/0001140361-18-033906-index.htm |
| 2020-10-30 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1349929/000121390020034105/0001213900-20-034105-index.htm |
| 2018-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1349929/000134992918000012/0001349929-18-000012-index.htm |
| 2018-11-19 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1349929/000134992918000014/0001349929-18-000014-index.htm |
| 2019-04-16 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1349929/000134992919000003/0001349929-19-000003-index.htm |
| 2019-05-20 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1349929/000134992919000005/0001349929-19-000005-index.htm |
| 2019-07-12 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000134992919000008/0001349929-19-000008-index.htm |
| 2019-08-19 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1349929/000134992919000010/0001349929-19-000010-index.htm |
| 2019-11-19 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1349929/000134992919000013/0001349929-19-000013-index.htm |
| 2020-05-29 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1349929/000134992920000005/0001349929-20-000005-index.htm |
| 2020-06-24 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1349929/000134992920000008/0001349929-20-000008-index.htm |
| 2020-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1349929/000134992920000013/0001349929-20-000013-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218011259/0001493152-18-011259-index.htm |
| 2018-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218011514/0001493152-18-011514-index.htm |
| 2018-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218011609/0001493152-18-011609-index.htm |
| 2018-08-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218012409/0001493152-18-012409-index.htm |
| 2018-09-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000149315218013540/0001493152-18-013540-index.htm |
| 2018-09-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218013580/0001493152-18-013580-index.htm |
| 2018-09-21 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315218013581/0001493152-18-013581-index.htm |
| 2018-10-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218014232/0001493152-18-014232-index.htm |
| 2018-10-09 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315218014233/0001493152-18-014233-index.htm |
| 2018-10-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315218014555/0001493152-18-014555-index.htm |
| 2018-10-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218014556/0001493152-18-014556-index.htm |
| 2018-10-18 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315218014635/0001493152-18-014635-index.htm |
| 2018-11-14 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | https://www.sec.gov/Archives/edgar/data/1349929/000149315218016096/0001493152-18-016096-index.htm |
| 2018-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218016154/0001493152-18-016154-index.htm |
| 2018-11-14 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315218016160/0001493152-18-016160-index.htm |
| 2018-11-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218016356/0001493152-18-016356-index.htm |
| 2018-11-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315218016357/0001493152-18-016357-index.htm |
| 2018-11-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218016501/0001493152-18-016501-index.htm |
| 2018-11-19 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315218016505/0001493152-18-016505-index.htm |
| 2018-11-21 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218016636/0001493152-18-016636-index.htm |
| 2018-11-21 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315218016637/0001493152-18-016637-index.htm |
| 2018-12-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000149315218017147/0001493152-18-017147-index.htm |
| 2018-12-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218017571/0001493152-18-017571-index.htm |
| 2018-12-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315218017847/0001493152-18-017847-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219000235/0001493152-19-000235-index.htm |
| 2019-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219000351/0001493152-19-000351-index.htm |
| 2019-01-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1349929/000149315219000364/0001493152-19-000364-index.htm |
| 2019-01-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1349929/000149315219000429/0001493152-19-000429-index.htm |
| 2019-01-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219000430/0001493152-19-000430-index.htm |
| 2019-01-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219000686/0001493152-19-000686-index.htm |
| 2019-01-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219000715/0001493152-19-000715-index.htm |
| 2019-01-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1349929/000149315219001022/0001493152-19-001022-index.htm |
| 2019-01-29 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1349929/000149315219001121/0001493152-19-001121-index.htm |
| 2019-01-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219001122/0001493152-19-001122-index.htm |
| 2019-02-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219001246/0001493152-19-001246-index.htm |
| 2019-02-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219002205/0001493152-19-002205-index.htm |
| 2019-04-01 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | https://www.sec.gov/Archives/edgar/data/1349929/000149315219004562/0001493152-19-004562-index.htm |
| 2019-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219005013/0001493152-19-005013-index.htm |
| 2019-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219005384/0001493152-19-005384-index.htm |
| 2019-04-19 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1349929/000149315219005670/0001493152-19-005670-index.htm |
| 2019-04-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219006084/0001493152-19-006084-index.htm |
| 2019-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1349929/000149315219006090/0001493152-19-006090-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219006616/0001493152-19-006616-index.htm |
| 2019-05-16 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | https://www.sec.gov/Archives/edgar/data/1349929/000149315219007590/0001493152-19-007590-index.htm |
| 2019-05-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219007930/0001493152-19-007930-index.htm |
| 2019-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219008530/0001493152-19-008530-index.htm |
| 2019-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219009438/0001493152-19-009438-index.htm |
| 2019-07-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219010411/0001493152-19-010411-index.htm |
| 2019-07-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219010893/0001493152-19-010893-index.htm |
| 2019-07-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219010896/0001493152-19-010896-index.htm |
| 2019-07-25 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219011078/0001493152-19-011078-index.htm |
| 2019-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219012198/0001493152-19-012198-index.htm |
| 2019-08-14 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | https://www.sec.gov/Archives/edgar/data/1349929/000149315219012516/0001493152-19-012516-index.htm |
| 2019-08-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219013113/0001493152-19-013113-index.htm |
| 2019-10-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219015939/0001493152-19-015939-index.htm |
| 2019-10-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219015950/0001493152-19-015950-index.htm |
| 2019-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219017035/0001493152-19-017035-index.htm |
| 2019-11-14 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | https://www.sec.gov/Archives/edgar/data/1349929/000149315219017462/0001493152-19-017462-index.htm |
| 2019-11-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315219018090/0001493152-19-018090-index.htm |
| 2020-02-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220002763/0001493152-20-002763-index.htm |
| 2020-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220003049/0001493152-20-003049-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220005198/0001493152-20-005198-index.htm |
| 2020-04-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000149315220007255/0001493152-20-007255-index.htm |
| 2020-04-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1349929/000149315220007256/0001493152-20-007256-index.htm |
| 2020-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220008767/0001493152-20-008767-index.htm |
| 2020-05-14 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | https://www.sec.gov/Archives/edgar/data/1349929/000149315220008768/0001493152-20-008768-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220010213/0001493152-20-010213-index.htm |
| 2020-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220011049/0001493152-20-011049-index.htm |
| 2020-06-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220011735/0001493152-20-011735-index.htm |
| 2020-06-26 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1349929/000149315220011939/0001493152-20-011939-index.htm |
| 2020-07-06 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1349929/000149315220012592/0001493152-20-012592-index.htm |
| 2020-07-20 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1349929/000149315220013611/0001493152-20-013611-index.htm |
| 2020-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220015667/0001493152-20-015667-index.htm |
| 2020-08-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220016574/0001493152-20-016574-index.htm |
| 2020-08-24 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315220016575/0001493152-20-016575-index.htm |
| 2020-09-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220017193/0001493152-20-017193-index.htm |
| 2020-09-03 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315220017194/0001493152-20-017194-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220017830/0001493152-20-017830-index.htm |
| 2020-09-15 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315220017831/0001493152-20-017831-index.htm |
| 2020-09-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220018261/0001493152-20-018261-index.htm |
| 2020-09-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220018620/0001493152-20-018620-index.htm |
| 2020-10-16 | S-4 | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315220019539/0001493152-20-019539-index.htm |
| 2020-10-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220019597/0001493152-20-019597-index.htm |
| 2020-10-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1349929/000149315220020062/0001493152-20-020062-index.htm |
| 2020-10-29 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1349929/000149315220020080/0001493152-20-020080-index.htm |
| 2020-10-29 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1349929/000149315220020086/0001493152-20-020086-index.htm |
| 2020-10-29 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1349929/000149315220020147/0001493152-20-020147-index.htm |
| 2020-11-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1349929/000149315220020331/0001493152-20-020331-index.htm |
| 2020-11-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1349929/000149315220020332/0001493152-20-020332-index.htm |
| 2019-01-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1349929/000153561019000051/0001535610-19-000051-index.htm |
| 2020-01-02 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1349929/000153561020000002/0001535610-20-000002-index.htm |
| 2020-11-02 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1349929/000175392620000345/0001753926-20-000345-index.htm |
| 2020-07-21 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1349929/999999999520001874/9999999995-20-001874-index.htm |
Cancer Genetics, Inc (CGIX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cancer Genetics, Inc (CGIX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 749%Institutional Ownership: 1692%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-01-14 | JOHN A ROBERTS | Chief Executive Officer | Buy | 100,000.00 | 0.23 | 22,500.00 | 112,200.00 | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000053/0000905718-19-000053-index.htm |
| 2019-01-14 | Geoffrey E. Harris | Director | Buy | 100,000.00 | 0.23 | 22,500.00 | 127,500.00 | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000057/0000905718-19-000057-index.htm |
| 2019-01-31 | Michael Glenn Miles | Chief Financial Officer | Buy | 150,000.00 | 0.23 | 34,500.00 | 150,000.00 | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000096/0000905718-19-000096-index.htm |
| 2019-01-31 | JOHN A ROBERTS | Chief Executive Officer | Buy | 185,436.00 | 0.23 | 42,650.28 | 297,636.00 | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000097/0000905718-19-000097-index.htm |
| 2019-01-14 | JOHN PAPPAJOHN | Director | Buy | 1,000,000.00 | 0.23 | 225,000.00 | 3,781,204.00 | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000055/0000905718-19-000055-index.htm |
| 2019-01-31 | JOHN PAPPAJOHN | Director | Buy | 1,000,000.00 | 0.23 | 230,000.00 | 4,781,204.00 | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000094/0000905718-19-000094-index.htm |
| 2019-01-31 | Edmund Cannon | Director | Buy | 43,479.00 | 0.23 | 10,000.17 | 61,873.00 | https://www.sec.gov/Archives/edgar/data/1349929/000090571819000095/0000905718-19-000095-index.htm |